image
Healthcare - Medical - Devices - NASDAQ - US
$ 2.92
-3.95 %
$ 115 M
Market Cap
-1.74
P/E
1. INTRINSIC VALUE

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States.[ Read More ]

The intrinsic value of one TELA stock under the base case scenario is HIDDEN Compared to the current market price of 2.92 USD, TELA Bio, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TELA

image
FINANCIALS
58.5 M REVENUE
41.13%
-44.1 M OPERATING INCOME
-12.99%
-46.7 M NET INCOME
-5.35%
-40.9 M OPERATING CASH FLOW
-0.27%
-599 K INVESTING CASH FLOW
68.00%
46.3 M FINANCING CASH FLOW
13.26%
19 M REVENUE
17.81%
-9.36 M OPERATING INCOME
19.06%
-10.4 M NET INCOME
17.68%
-8.98 M OPERATING CASH FLOW
16.02%
-122 K INVESTING CASH FLOW
-182.09%
98 K FINANCING CASH FLOW
2060.00%
Balance Sheet Decomposition TELA Bio, Inc.
image
Current Assets 71.7 M
Cash & Short-Term Investments 46.7 M
Receivables 9.74 M
Other Current Assets 15.3 M
Non-Current Assets 6.32 M
Long-Term Investments 0
PP&E 3.94 M
Other Non-Current Assets 2.38 M
Current Liabilities 17 M
Accounts Payable 1.67 M
Short-Term Debt 565 K
Other Current Liabilities 14.7 M
Non-Current Liabilities 42.2 M
Long-Term Debt 40.5 M
Other Non-Current Liabilities 1.68 M
EFFICIENCY
Earnings Waterfall TELA Bio, Inc.
image
Revenue 58.5 M
Cost Of Revenue 18.3 M
Gross Profit 40.1 M
Operating Expenses 84.2 M
Operating Income -44.1 M
Other Expenses 2.59 M
Net Income -46.7 M
RATIOS
68.62% GROSS MARGIN
68.62%
-75.40% OPERATING MARGIN
-75.40%
-79.83% NET MARGIN
-79.83%
-247.15% ROE
-247.15%
-59.79% ROA
-59.79%
-74.21% ROIC
-74.21%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis TELA Bio, Inc.
image
Net Income -46.7 M
Depreciation & Amortization 808 K
Capital Expenditures -611 K
Stock-Based Compensation 5.03 M
Change in Working Capital -1.67 M
Others 5.73 M
Free Cash Flow -41.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets TELA Bio, Inc.
image
Wall Street analysts predict an average 1-year price target for TELA of $10 , with forecasts ranging from a low of $8 to a high of $14 .
TELA Lowest Price Target Wall Street Target
8 USD 173.97%
TELA Average Price Target Wall Street Target
10 USD 242.47%
TELA Highest Price Target Wall Street Target
14 USD 379.45%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership TELA Bio, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
2.02 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
410 K USD 4
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
110 K USD 3
9-12 MONTHS
Date Value Insider Amount Avg Price
3 weeks ago
Oct 24, 2024
Bought 145 K USD
Cuca Roberto
COO and CFO
+ 64444
2.25 USD
3 weeks ago
Oct 24, 2024
Bought 50 K USD
Talmo Paul
Chief Technology Officer
+ 22222
2.25 USD
3 weeks ago
Oct 24, 2024
Bought 200 K USD
KOBLISH ANTONY
Chief Executive Officer
+ 88888
2.25 USD
3 weeks ago
Oct 24, 2024
Bought 15 K USD
Firestone Gregory A.
Chief Commercial Officer
+ 6666
2.25 USD
4 months ago
Jun 28, 2024
Sell 1.79 M USD
ORBIMED ADVISORS LLC
10 percent owner
- 378000
4.74 USD
4 months ago
Jul 01, 2024
Sell 64.1 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 13700
4.68 USD
4 months ago
Jul 02, 2024
Sell 166 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 36600
4.54 USD
2 years ago
Jul 14, 2022
Bought 40 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 5000
8.01 USD
4 years ago
Aug 28, 2020
Bought 1.28 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 100
12.85 USD
4 years ago
Aug 14, 2020
Bought 119 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 9179
12.95 USD
4 years ago
Aug 11, 2020
Bought 10.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 821
12.95 USD
4 years ago
Aug 04, 2020
Bought 130 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 10200
12.72 USD
4 years ago
Aug 03, 2020
Bought 16.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 1400
11.86 USD
4 years ago
Jul 31, 2020
Bought 377 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 31825
11.86 USD
4 years ago
Jul 30, 2020
Bought 90.4 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 7400
12.22 USD
4 years ago
Jul 29, 2020
Bought 156 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 12600
12.39 USD
4 years ago
Jul 28, 2020
Bought 125 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 10000
12.48 USD
4 years ago
Apr 28, 2020
Bought 47.4 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 5000
9.48 USD
4 years ago
Apr 23, 2020
Bought 150 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 15000
9.98 USD
4 years ago
Apr 22, 2020
Bought 91.4 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 10000
9.14 USD
4 years ago
Apr 21, 2020
Bought 25.3 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 3037
8.32 USD
4 years ago
Apr 20, 2020
Bought 56.4 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 7000
8.06 USD
4 years ago
Apr 17, 2020
Bought 206 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 25000
8.25 USD
4 years ago
Apr 16, 2020
Bought 140 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 17500
8 USD
4 years ago
Apr 15, 2020
Bought 99.9 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 12500
7.99 USD
4 years ago
Apr 14, 2020
Bought 121 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 15000
8.07 USD
4 years ago
Apr 13, 2020
Bought 79.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 10000
7.96 USD
4 years ago
Apr 09, 2020
Bought 212 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 25000
8.47 USD
4 years ago
Apr 08, 2020
Bought 126 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 15000
8.37 USD
4 years ago
Apr 07, 2020
Bought 164 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 20000
8.2 USD
4 years ago
Apr 06, 2020
Bought 145 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 17866
8.1 USD
4 years ago
Apr 03, 2020
Bought 77.2 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 9634
8.01 USD
4 years ago
Apr 02, 2020
Bought 120 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 15000
8.01 USD
4 years ago
Apr 01, 2020
Bought 112 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
10 percent owner, other: See Remarks
+ 15000
7.47 USD
11 months ago
Dec 05, 2023
Bought 14.7 K USD
Firestone Gregory A.
Chief Business Officer
+ 2600
5.6494 USD
1 year ago
Nov 14, 2023
Bought 44.9 K USD
Cuca Roberto
COO and CFO
+ 10000
4.4938 USD
1 year ago
Nov 14, 2023
Bought 50 K USD
KOBLISH ANTONY
Chief Executive Officer
+ 11000
4.5433 USD
1 year ago
Apr 19, 2023
Sell 1.26 M USD
ORBIMED ADVISORS LLC
10 percent owner
- 136000
9.3 USD
1 year ago
Apr 20, 2023
Sell 267 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 28300
9.43 USD
1 year ago
Apr 21, 2023
Sell 261 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 27700
9.41 USD
2 years ago
Nov 03, 2022
Bought 148 K USD
Opaleye Management Inc.
Director
+ 19000
7.8119 USD
2 years ago
Nov 03, 2022
Bought 9.86 K USD
Opaleye Management Inc.
Director
+ 1262
7.8119 USD
2 years ago
Oct 11, 2022
Bought 120 K USD
Opaleye Management Inc.
Director
+ 15000
8 USD
2 years ago
Oct 11, 2022
Bought 8 K USD
Opaleye Management Inc.
Director
+ 1000
8 USD
2 years ago
Sep 23, 2022
Bought 52 K USD
Opaleye Management Inc.
10 percent owner
+ 6500
7.9942 USD
2 years ago
Sep 23, 2022
Bought 2.43 K USD
Opaleye Management Inc.
10 percent owner
+ 304
7.9942 USD
2 years ago
Sep 19, 2022
Bought 137 K USD
Opaleye Management Inc.
10 percent owner
+ 17000
8.088 USD
2 years ago
Sep 19, 2022
Bought 8.09 K USD
Opaleye Management Inc.
10 percent owner
+ 1000
8.088 USD
2 years ago
Sep 16, 2022
Bought 16.2 K USD
Opaleye Management Inc.
10 percent owner
+ 2000
8.0831 USD
2 years ago
Sep 15, 2022
Bought 28.4 K USD
Opaleye Management Inc.
10 percent owner
+ 3500
8.1 USD
2 years ago
Sep 16, 2022
Bought 3.01 K USD
Opaleye Management Inc.
10 percent owner
+ 372
8.0831 USD
2 years ago
Sep 15, 2022
Bought 5.33 K USD
Opaleye Management Inc.
10 percent owner
+ 658
8.1 USD
2 years ago
Aug 16, 2022
Bought 40.5 K USD
Opaleye Management Inc.
10 percent owner
+ 5000
8.0991 USD
2 years ago
Aug 16, 2022
Bought 1.79 K USD
Opaleye Management Inc.
10 percent owner
+ 221
8.0991 USD
2 years ago
Aug 17, 2022
Bought 4 M USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 500000
8 USD
2 years ago
Aug 16, 2022
Bought 2.4 M USD
Opaleye Management Inc.
10 percent owner
+ 300000
8 USD
2 years ago
Aug 16, 2022
Bought 120 K USD
Opaleye Management Inc.
director:
+ 15000
8 USD
2 years ago
Aug 01, 2022
Bought 35.8 K USD
Opaleye Management Inc.
10 percent owner
+ 4500
7.9598 USD
2 years ago
Aug 01, 2022
Bought 3.81 K USD
Opaleye Management Inc.
10 percent owner
+ 479
7.9598 USD
2 years ago
Aug 10, 2022
Bought 98 K USD
Opaleye Management Inc.
director:
+ 11500
8.5223 USD
2 years ago
Aug 10, 2022
Bought 4.08 K USD
Opaleye Management Inc.
10 percent owner
+ 479
8.5223 USD
2 years ago
Aug 01, 2022
Bought 35.8 K USD
Opaleye Management Inc.
10 percent owner
+ 4500
7.9598 USD
2 years ago
Aug 01, 2022
Bought 3.81 K USD
Opaleye Management Inc.
director:
+ 479
7.9598 USD
2 years ago
Jul 22, 2022
Bought 40.1 K USD
Opaleye Management Inc.
director:
+ 5000
8.021 USD
2 years ago
Jul 22, 2022
Bought 1.6 K USD
Opaleye Management Inc.
10 percent owner
+ 200
8.021 USD
2 years ago
Jul 21, 2022
Bought 76.3 K USD
Opaleye Management Inc.
director:
+ 9500
8.0297 USD
2 years ago
Jul 21, 2022
Bought 6.73 K USD
Opaleye Management Inc.
10 percent owner
+ 833
8.0768 USD
2 years ago
Jul 20, 2022
Bought 36.3 K USD
Opaleye Management Inc.
director:
+ 4500
8.0768 USD
2 years ago
Jul 20, 2022
Bought 4.85 K USD
Opaleye Management Inc.
10 percent owner
+ 600
8.0768 USD
2 years ago
Jul 11, 2022
Bought 40.2 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
8.03 USD
2 years ago
Jul 06, 2022
Bought 40.4 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
8.07 USD
2 years ago
Jun 30, 2022
Bought 37.6 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
7.52 USD
2 years ago
Jun 27, 2022
Bought 36.1 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
7.22 USD
2 years ago
Jun 24, 2022
Bought 14 K USD
Opaleye Management Inc.
director:
+ 2000
6.99 USD
2 years ago
Jun 22, 2022
Bought 14 K USD
Opaleye Management Inc.
10 percent owner
+ 2000
6.99 USD
2 years ago
Jun 22, 2022
Bought 2.8 K USD
Opaleye Management Inc.
10 percent owner
+ 400
6.99 USD
2 years ago
Jun 22, 2022
Bought 32.4 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
6.47 USD
2 years ago
Jun 16, 2022
Bought 31.2 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
6.25 USD
2 years ago
Jun 13, 2022
Bought 29.5 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
5.9 USD
2 years ago
Jun 10, 2022
Bought 140 K USD
Opaleye Management Inc.
10 percent owner
+ 25000
5.6024 USD
2 years ago
Jun 10, 2022
Bought 14 K USD
Opaleye Management Inc.
director:
+ 2500
5.6024 USD
2 years ago
Jun 08, 2022
Bought 29 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
5.8 USD
2 years ago
Jun 03, 2022
Bought 30 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
5.99 USD
2 years ago
Jun 07, 2022
Bought 82.5 K USD
Cuca Roberto
COO and CFO
+ 15000
5.5 USD
2 years ago
May 31, 2022
Bought 35 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
6.99 USD
2 years ago
May 25, 2022
Bought 37.2 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
7.43 USD
2 years ago
May 20, 2022
Bought 43.9 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
8.79 USD
2 years ago
May 17, 2022
Bought 44.8 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
8.96 USD
2 years ago
May 12, 2022
Bought 43 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
8.61 USD
2 years ago
May 09, 2022
Bought 44.1 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
8.82 USD
2 years ago
May 05, 2022
Bought 47.8 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
9.55 USD
2 years ago
May 02, 2022
Bought 47.6 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
9.53 USD
2 years ago
Apr 27, 2022
Bought 45.4 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
9.09 USD
2 years ago
Apr 25, 2022
Bought 92.4 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 10000
9.24 USD
2 years ago
Apr 14, 2022
Bought 49 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 5000
9.8 USD
2 years ago
Mar 31, 2022
Bought 7.83 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 684
11.45 USD
2 years ago
Mar 29, 2022
Bought 30.8 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 2645
11.65 USD
2 years ago
Mar 22, 2022
Bought 1.58 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 136
11.65 USD
2 years ago
Mar 16, 2022
Bought 40.6 K USD
EW Healthcare Partners Fund 2-UGP, LLC
director:
+ 3473
11.68 USD
2 years ago
Feb 24, 2022
Bought 65.4 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5572
11.74 USD
2 years ago
Feb 23, 2022
Bought 8.82 M USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 750657
11.75 USD
2 years ago
Feb 22, 2022
Bought 42 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 3579
11.74 USD
2 years ago
Feb 18, 2022
Bought 29.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 2520
11.75 USD
2 years ago
Feb 17, 2022
Bought 79.9 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 6810
11.73 USD
2 years ago
Feb 16, 2022
Bought 117 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 10000
11.72 USD
2 years ago
Feb 15, 2022
Bought 341 USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 29
11.75 USD
2 years ago
Feb 14, 2022
Bought 118 USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 10
11.75 USD
2 years ago
Feb 11, 2022
Bought 83.1 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 7082
11.74 USD
2 years ago
Feb 10, 2022
Bought 6.11 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 520
11.75 USD
2 years ago
Feb 09, 2022
Bought 15.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 1327
11.75 USD
2 years ago
Feb 08, 2022
Bought 5.88 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 500
11.75 USD
2 years ago
Jan 31, 2022
Bought 22.9 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 1950
11.74 USD
2 years ago
Jan 28, 2022
Bought 56.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5000
11.33 USD
2 years ago
Jan 27, 2022
Bought 57.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5000
11.51 USD
2 years ago
Jan 26, 2022
Bought 58.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 4993
11.74 USD
2 years ago
Jan 25, 2022
Bought 45.8 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 3846
11.92 USD
2 years ago
Jan 24, 2022
Bought 58.4 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5000
11.68 USD
2 years ago
Jan 14, 2022
Bought 6.81 M USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 567467
12 USD
2 years ago
Jan 12, 2022
Bought 62.5 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5000
12.5 USD
2 years ago
Jan 11, 2022
Bought 61.9 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5000
12.38 USD
2 years ago
Jan 10, 2022
Bought 17.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 1409
12.46 USD
2 years ago
Dec 31, 2021
Bought 73.9 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5928
12.46 USD
2 years ago
Dec 20, 2021
Bought 52.5 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 4300
12.22 USD
2 years ago
Dec 16, 2021
Bought 62.9 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5050
12.45 USD
2 years ago
Dec 15, 2021
Bought 62.2 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5000
12.43 USD
2 years ago
Dec 14, 2021
Bought 123 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 10000
12.33 USD
2 years ago
Dec 10, 2021
Bought 17.3 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 1387
12.49 USD
2 years ago
Dec 08, 2021
Bought 17.7 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 1425
12.39 USD
2 years ago
Dec 07, 2021
Bought 137 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 11148
12.32 USD
2 years ago
Dec 06, 2021
Bought 124 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 10000
12.39 USD
2 years ago
Dec 02, 2021
Bought 17.1 K USD
Cuca Roberto
COO and CFO
+ 1351
12.67 USD
2 years ago
Dec 01, 2021
Bought 22.5 K USD
Cuca Roberto
COO and CFO
+ 1780
12.64 USD
2 years ago
Nov 30, 2021
Bought 10.4 K USD
Cuca Roberto
COO and CFO
+ 838
12.43 USD
2 years ago
Nov 29, 2021
Bought 5.33 K USD
Cuca Roberto
COO and CFO
+ 423
12.6 USD
2 years ago
Nov 23, 2021
Bought 6.44 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 516
12.49 USD
2 years ago
Nov 22, 2021
Bought 41.2 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 3295
12.49 USD
3 years ago
Nov 18, 2021
Bought 54.8 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 4419
12.41 USD
3 years ago
Nov 17, 2021
Bought 12.5 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 1000
12.5 USD
3 years ago
Nov 10, 2021
Bought 12.5 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 1000
12.5 USD
3 years ago
Oct 27, 2021
Bought 63.2 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5088
12.43 USD
3 years ago
Oct 20, 2021
Bought 26 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 2090
12.42 USD
3 years ago
Oct 13, 2021
Bought 2.5 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 200
12.5 USD
3 years ago
Oct 11, 2021
Bought 3.54 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 283
12.5 USD
3 years ago
Oct 06, 2021
Bought 1.38 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 110
12.5 USD
3 years ago
Sep 21, 2021
Bought 8.76 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 695
12.6 USD
3 years ago
Sep 20, 2021
Bought 11.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 924
12.58 USD
3 years ago
Sep 17, 2021
Bought 4.06 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 322
12.61 USD
3 years ago
Sep 15, 2021
Bought 124 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 10000
12.43 USD
3 years ago
Sep 13, 2021
Bought 124 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 10000
12.43 USD
3 years ago
Sep 14, 2021
Bought 123 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 10000
12.27 USD
3 years ago
Sep 13, 2021
Bought 1.43 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 115
12.43 USD
3 years ago
Sep 10, 2021
Bought 178 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 14436
12.31 USD
3 years ago
Sep 09, 2021
Bought 163 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 13087
12.46 USD
3 years ago
Sep 08, 2021
Bought 622 USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 47
13.24 USD
3 years ago
Sep 07, 2021
Bought 1.67 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 131
12.77 USD
3 years ago
Jun 14, 2021
Bought 1 M USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 79970
12.5 USD
3 years ago
Jun 07, 2021
Bought 130 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 10000
12.99 USD
3 years ago
Jun 03, 2021
Bought 2.65 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 201
13.17 USD
3 years ago
May 24, 2021
Bought 17 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 1278
13.31 USD
3 years ago
May 21, 2021
Bought 20.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 1549
13.3 USD
3 years ago
May 20, 2021
Bought 113 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 8525
13.3 USD
3 years ago
May 19, 2021
Bought 6.05 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 450
13.44 USD
3 years ago
May 18, 2021
Bought 47.2 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 3546
13.3 USD
3 years ago
May 14, 2021
Bought 74 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5658
13.08 USD
3 years ago
May 14, 2021
Bought 93.4 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 7500
12.45 USD
3 years ago
May 13, 2021
Bought 119 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 10000
11.87 USD
3 years ago
May 12, 2021
Bought 62.4 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5000
12.49 USD
3 years ago
May 11, 2021
Bought 95.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 7500
12.75 USD
3 years ago
May 10, 2021
Bought 97 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 7500
12.93 USD
3 years ago
May 07, 2021
Bought 98.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 7500
13.15 USD
3 years ago
May 06, 2021
Bought 85.5 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 6499
13.15 USD
3 years ago
May 05, 2021
Bought 99.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 7500
13.28 USD
3 years ago
Apr 28, 2021
Bought 2.68 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 200
13.41 USD
3 years ago
Apr 27, 2021
Bought 202 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 15000
13.49 USD
3 years ago
Apr 23, 2021
Bought 67.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5000
13.51 USD
3 years ago
Apr 22, 2021
Bought 67.7 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5000
13.54 USD
3 years ago
Apr 21, 2021
Bought 4.96 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 365
13.59 USD
3 years ago
Apr 20, 2021
Bought 63.3 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 4678
13.54 USD
3 years ago
Apr 19, 2021
Bought 8.51 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 625
13.61 USD
3 years ago
Apr 12, 2021
Bought 39.3 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 2893
13.57 USD
3 years ago
Apr 08, 2021
Bought 2.82 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 206
13.67 USD
3 years ago
Mar 26, 2021
Bought 488 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 37851
12.88 USD
3 years ago
Mar 25, 2021
Bought 65.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5000
13.11 USD
3 years ago
Mar 24, 2021
Bought 37.1 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 2660
13.94 USD
3 years ago
Mar 23, 2021
Bought 138 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 10000
13.79 USD
3 years ago
Feb 04, 2021
Bought 40.3 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 2822
14.29 USD
3 years ago
Feb 02, 2021
Bought 3.52 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 250
14.08 USD
3 years ago
Feb 01, 2021
Bought 15.8 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 1119
14.16 USD
3 years ago
Jan 29, 2021
Bought 108 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 7760
13.93 USD
3 years ago
Jan 28, 2021
Bought 191 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 13950
13.68 USD
3 years ago
Jan 27, 2021
Bought 70.2 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 5000
14.03 USD
3 years ago
Jan 26, 2021
Bought 22 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 1544
14.24 USD
3 years ago
Jan 15, 2021
Bought 10.6 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 763
13.88 USD
3 years ago
Jan 14, 2021
Bought 127 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 9075
13.96 USD
3 years ago
Jan 13, 2021
Bought 97.3 K USD
EW HEALTHCARE PARTNERS FUND 2, L.P.
+ 7002
13.9 USD
4 years ago
Dec 17, 2019
Sell 408 K USD
RTW INVESTMENTS, LP
10 percent owner
- 36000
11.3227 USD
4 years ago
Dec 13, 2019
Bought 277 K USD
RTW INVESTMENTS, LP
10 percent owner
+ 23900
11.595 USD
5 years ago
Nov 08, 2019
Bought 2 M USD
Quaker BioVentures II LP
10 percent owner
+ 153846
13 USD
5 years ago
Nov 08, 2019
Bought 987 K USD
Zuga Matt
Director
+ 75901
13 USD
5 years ago
Nov 08, 2019
Bought 133 K USD
Zuga Matt
Director
+ 10220
13 USD
5 years ago
Nov 08, 2019
Bought 987 K USD
Azarbarzin Kurt
Director
+ 75901
13 USD
5 years ago
Nov 08, 2019
Bought 133 K USD
Azarbarzin Kurt
Director
+ 10220
13 USD
5 years ago
Nov 08, 2019
Bought 2 M USD
Oliva Adele C
director, 10 percent owner:
+ 153846
13 USD
5 years ago
Nov 08, 2019
Bought 5 M USD
ORBIMED ADVISORS LLC
10 percent owner
+ 384615
13 USD
7. News
TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript TELA Bio, Inc. (NASDAQ:TELA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President, Gilmartin Group Tony Koblish - President & Chief Executive Officer Roberto Cuca - Chief Operating Officer & Chief Financial Officer Conference Call Participants Caitlin Cronin - Canaccord Genuity Frank Takkinen - Lake Street Capital Markets Michael Sarcone - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 1 week ago
TELA Bio, Inc. (TELA) Reports Q3 Loss, Lags Revenue Estimates TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago. zacks.com - 1 week ago
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,400 shares of its common stock to six newly-hired employees, with a grant date of November 1, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. globenewswire.com - 2 weeks ago
TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares MALVERN, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced the closing of its previously announced underwritten public offering of 14,670,000 shares of its common stock, including the exercise in full of the underwriters' option to purchase additional shares, at a price to the public of $2.25 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,800,000 shares of common stock at a public offering price of $2.2499 per pre-funded warrant, which represents the per share public offering price for the shares of common stock less the $0.0001 per share exercise price for each pre-funded warrant, for gross proceeds of $46 million, before deducting underwriting discounts and commissions and other estimated offering expenses and assuming no exercise of the pre-funded warrants. All shares of common stock and pre-funded warrants were sold by TELA. globenewswire.com - 3 weeks ago
TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants MALVERN, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $2.25 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,800,000 shares of common stock at a public offering price of $2.2499 per pre-funded warrant, which represents the per share public offering price for the shares of common stock less the $0.0001 per share exercise price for each pre-funded warrant, collectively, for gross proceeds of $40 million, before deducting underwriting discounts and commissions and other estimated offering expenses and assuming no exercise of the pre-funded warrants. In addition, TELA has granted the underwriters a 30-day option to purchase up to an additional 2,670,000 shares of its common stock at the public offering price for the common stock, less underwriting discounts and commissions. All shares of common stock and pre-funded warrants are being offered by TELA. The offering is expected to close on or about October 24, 2024, subject to the satisfaction of customary closing conditions. globenewswire.com - 3 weeks ago
TELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of its common stock. In addition, TELA expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the securities to be sold in the proposed offering at the public offering price for the common stock, less underwriting discounts and commissions. All shares of common stock and pre-funded warrants are being offered by TELA. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the proposed offering. globenewswire.com - 3 weeks ago
TELA Bio to Announce Third Quarter 2024 Financial Results MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2024 financial results on Thursday, November 7, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. globenewswire.com - 1 month ago
TELA Bio, Inc. (TELA) Q2 2024 Earnings Call Transcript TELA Bio, Inc. (NASDAQ:TELA ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President of Gilmartin Group Antony Koblish - Co-founder, President & CEO Roberto Cuca - COO & CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity Matthew O'Brien - Piper Sandler Michael Sarcone - Jefferies David Turkaly - Citizens JMP Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Second Quarter 2024 Earnings Conference Call. [Operator Instructions]. seekingalpha.com - 3 months ago
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.46 per share a year ago. zacks.com - 3 months ago
TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the second quarter ended June 30, 2024. globenewswire.com - 3 months ago
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Aug. 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 16,000 shares of its common stock to nine newly-hired employees, with a grant date of August 6, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. globenewswire.com - 3 months ago
TELA Bio to Announce Second Quarter 2024 Financial Results MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2024 financial results on Monday, August 12, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. globenewswire.com - 3 months ago
8. Profile Summary

TELA Bio, Inc. TELA

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 115 M
Dividend Yield 0.00%
Description TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Contact 1 Great Valley Parkway, Malvern, PA, 19355 https://www.telabio.com
IPO Date Nov. 8, 2019
Employees 227
Officers Mr. D. Taylor Ocasio General Counsel & Corporate Secretary Mr. Gregory A. Firestone Chief Commercial Officer Ms. Megan Smeykal Vice President, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer Mr. Antony Koblish Co-founder, President, Chief Executive Officer & Director Mr. Paul Talmo Chief Technology Officer Mr. Peter C. Murphy Chief Commercial Officer Louisa Smith Investor Relations Contact Officer Ms. Jennifer Lou Armstrong Senior Vice President of Human Resources Mr. Roberto E. Cuca J.D. Chief Financial Officer & Chief Operating Officer Mr. Michael Leonard Senior Vice President of Technical Operations